Cognition Therapeutics Secures Composition of Matter Patent for Zervimesine Extending Protection to 2045

A polymorphic crystalline form patent for zervimesine (CT1812) now positions Cognition Therapeutics with exclusivity through 2045, and potentially 2050 with a standard five-year extension, reshaping the competitive and regulatory timeline for any future generic entrants in the neurodegenerative space.

The USPTO issued a Notice of Allowance for patent application 19/563,468, covering three distinct claims: the polymorphic crystalline form itself as a composition of matter, a proprietary production process for manufacturing zervimesine, and therapeutic methods for treating Alzheimer's disease, geographic atrophy, and dementia with Lewy bodies (DLB). The patent's formal title references the fumarate salt of the compound's full chemical name, signalling a formulation-level differentiation from the parent molecule.

For regulatory and formulation teams, the crystalline form distinction carries direct process validation implications. Cognition states the new polymorphic configuration delivers greater thermodynamic and chemical stability compared to the parent compound, a property difference that will require characterisation data in any NDA or IND amendment submissions, and that generic applicants would need to navigate under 21 CFR Part 314 paragraph IV certification or design-around strategies.

The company confirmed it intends to deploy this new crystalline form in registrational trials for DLB psychosis, following Phase 2 SHIMMER study efficacy signals. Productive discussions with the FDA were held in May 2026, with meeting minutes pending to confirm alignment on the registrational program's next steps. DLB psychosis currently has no approved treatments, which may support an expedited pathway designation discussion with the agency.

Zervimesine remains under active Phase 2 investigation in the START Study (NCT05531656) for mild cognitive impairment and early Alzheimer's disease. The broader program has been supported by nearly $200 million in NIH and related foundation grants, providing a non-dilutive funding base that has sustained the clinical and CMC development work underpinning this patent estate.

The measurable checkpoint ahead is receipt of the USPTO-issued patent certificate and confirmation of FDA meeting minutes, both of which will determine the regulatory and manufacturing specifications locked into the registrational trial design.

Source: Cognition Therapeutics via GlobeNewswire, June 16, 2026.